Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review
oleh: Gaurav Nepal, Mahika Khurana, Domenica Herrera Bucheli, Siddhartha Bhandari, Utsav Joshi, Riwaj Bhagat, Jessica Holly Rehrig, Prasun Pudasainee, Yow Ka Shing, Juan Fernando Ortiz, Rajeev Ojha, Bikram Prasad Gajurel, Jonathan Quinonez, Samir Ruxmohan, Trevine Albert, Steven Licata, Joel Stien
| Format: | Article |
|---|---|
| Diterbitkan: | MDPI AG 2022-01-01 |
Deskripsi
Primary Central Nervous System Lymphoma (PCNSL) is a rare variant of Non-Hodgkin Lymphoma (NHL) representing 1–2% of all NHL cases. PCNSL is defined as a lymphoma that occurs in the brain, spinal cord, leptomeninges, or eyes. Efforts to treat PCNSL by traditional chemotherapy and radiotherapy have generally been unsuccessful as a significant proportion of patients have frequent relapses or are refractory to treatment. The prognosis of patients with Refractory or Relapsed (R/R) PCNSL is abysmal. The optimal treatment for R/R PCNSL is poorly defined as there are only a limited number of studies in this setting. Several studies have recently shown that ibrutinib, a Bruton tyrosine kinase (BTK) inhibitor, has promising results in the treatment of R/R PCNSL. However, these are preliminary studies with a limited sample size. In this systematic review, we explored and critically appraised the evidence about the efficacy of the novel agent ibrutinib in treating R/R PCNSL.